Global Blood Therapeutics (GBT) Given a $96.00 Price Target by Cantor Fitzgerald Analysts
Several other equities research analysts also recently commented on GBT. JPMorgan Chase & Co. reiterated a buy rating and set a $75.00 target price on shares of Global Blood Therapeutics in a report on Sunday, August 5th. SunTrust Banks set a $70.00 target price on Global Blood Therapeutics and gave the company a buy rating in a report on Sunday, August 5th. Piper Jaffray Companies initiated coverage on Global Blood Therapeutics in a report on Monday, August 6th. They set an overweight rating and a $80.00 target price on the stock. Wedbush reiterated an outperform rating and set a $73.00 target price on shares of Global Blood Therapeutics in a report on Monday, August 6th. Finally, BidaskClub upgraded Global Blood Therapeutics from a strong sell rating to a sell rating in a report on Wednesday, August 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and fourteen have issued a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus price target of $83.20.
Shares of NASDAQ:GBT opened at $45.45 on Monday. Global Blood Therapeutics has a one year low of $30.15 and a one year high of $68.05.
Hedge funds have recently bought and sold shares of the business. State of Wisconsin Investment Board increased its holdings in Global Blood Therapeutics by 40.6% during the 2nd quarter. State of Wisconsin Investment Board now owns 52,300 shares of the company’s stock worth $2,364,000 after purchasing an additional 15,100 shares during the last quarter. Nexthera Capital LP increased its holdings in Global Blood Therapeutics by 28.2% during the 2nd quarter. Nexthera Capital LP now owns 404,092 shares of the company’s stock worth $18,265,000 after purchasing an additional 88,945 shares during the last quarter. Botty Investors LLC increased its holdings in shares of Global Blood Therapeutics by 45.7% in the 3rd quarter. Botty Investors LLC now owns 129,435 shares of the company’s stock valued at $4,919,000 after acquiring an additional 40,595 shares during the last quarter. American Century Companies Inc. bought a new stake in shares of Global Blood Therapeutics in the 2nd quarter valued at approximately $2,680,000. Finally, State Board of Administration of Florida Retirement System increased its holdings in shares of Global Blood Therapeutics by 19.7% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 23,669 shares of the company’s stock valued at $1,070,000 after acquiring an additional 3,900 shares during the last quarter.
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.
Featured Story: How much can an individual set aside as a catch-up contribution?
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.